ORLANDO, FL — (Marketwired) — 04/28/17 — MEDITE Cancer Diagnostics, Inc. (MDIT) (the “Company”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced the restructuring of its organization in Germany to position the Company for revenue growth and profitability.

Effective immediately, three new reporting lines have been established for the organization in Germany. All sales, marketing and sales fulfillment personnel and activities will report into Jeff Rencher, Chief Marketing and Business Development Officer. All manufacturing, R&D, technical service and quality management personnel and activities will report into Stephen Von Rump, Chief Commercialization and Strategy Officer. All financial personnel and activities will report into Susan Weisman, Chief Financial Officer. Mr. Rencher, Mr. Von Rump and Ms. Weisman all report directly to David Patterson, Chief Executive Officer of the Company.

“The purpose of this reorganization is to position the Company for the next level of growth and profitability,” said Mr. Patterson. “To reach our goals of globalization and revenue increase requires a different approach to the business. We needed to integrate the organization and put in place the infrastructure needed to achieve those goals.”

Near-term objectives for the new organization include refocusing sales activities to better serve the existing customer base, pursue new sales opportunities, and revamping manufacturing, service and R&D activities to improve quality and customer support, and better align the company’s product portfolio to new global opportunities.

About MEDITE Cancer Diagnostics, Inc.
MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 80 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE’s ability to maintain and grow its revenues. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: www.medite-group.com

Investor Contact:
David Patterson
CEO
317-341-3589

Source: MEDITE Cancer Diagnostics, Inc.